Jennifer King, PhD, of the Lung Cancer Alliance, gives her perspective on major themes of this year’s meeting: the stigma of lung cancer, the changing face of who is affected, early detection, and advances in immunotherapy.
Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/...
Howard Jack West, MD, of the Swedish Cancer Institute, summarizes three important papers: anlotinib as third-line treatment for refractory advanced non–small cell lung cancer; the ...
Heather A. Wakelee, MD, of Stanford University discusses the study that explored the question of whether adding bevacizumab to adjuvant chemotherapy is beneficial in the setting of...
Naiyer A. Rizvi, MD, of Columbia University, offers an update on immune checkpoint inhibitors in non–small cell lung cancer: what’s new and what’s next.
Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a c...
